Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed With Type I Diabetes
Status:
Recruiting
Trial end date:
2024-10-17
Target enrollment:
Participant gender:
Summary
An open label, parallel single centre trial of Wharton's Jelly derived allogenic mesenchymal
stromal cells repeated treatment to preserve endogenous insulin production in adult patients
diagnosed with type 1 diabetes